Your session is about to expire
← Back to Search
Mindfulness App for Gynecologic Cancers (MECCA Trial)
MECCA Trial Summary
This trial will test whether the Headspace smartphone app can help reduce stress in patients with endometrial or cervical cancer.
MECCA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMECCA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MECCA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there open spots for participants in this scientific experiment?
"Affirmative. Clinicaltrials.gov indicates that this medical study, which originated on July 25th 2020, is currently enrolling patients and looking to recruit 120 participants from a single location."
How many subjects are partaking in this experiment?
"That is correct. Referring to clinicaltrials.gov, we can see that the trial was first put up on July 25th 2020 and it has been recently updated on February 18th 2022. The research project requires 120 individuals from a single centre."
What key goals is this research endeavor attempting to achieve?
"This clinical trial will be evaluated over a time-frame extending from enrolment to 6 weeks after treatment for cervical cancer, and opiate usage in endometrial cancer. Secondary objectives include the completion of Functional Assessment of Cancer Therapy-General forms at various points during the study, patient satisfaction surveys, and monitoring complication rates among both groups."
Is the upper age limit for this experimentation open to those over 45 years old?
"This experiment is inviting volunteers aged 18 and older, but no more than 90 years old."
Who has the opportunity to be a participant in this investigation?
"Criteria for enrollment in this clinical trial is strict: the patient must have endometrial neoplasms and be between 18-90 years old. The team behind this study hopes to recruit roughly 120 patients."
Share this study with friends
Copy Link
Messenger